Background Guazuma ulmifolia is traditionally used for liver disorders, but its protective mechanisms against heavy metal toxicity are poorly defined. This study evaluated the phytochemical profile and hepatoprotective mechanisms of G. ulmifolia butanol extract (Gul-BuOH) against cadmium-induced liver injury. Methods and findings Gul-BuOH was chemically profiled by UPLC-PDA-ESI–qTOF-MS/MS. Cadmium hepatotoxicity was induced in rats, followed by Gul-BuOH treatment (100 and 200 mg/kg). Liver injury, oxidative stress, inflammation, gene expression (Let-7a, HOTAIR), histopathology, HO-1/Sirt-1 immunoreactivity, and serum metabolomic changes were assessed. Chemical profiling led to the annotation of 42 compounds, including mainly flavonoids and phenolic acids, highlighting the rich phytochemical composition of G. ulmifolia. CdCl2 exposure increased hepatic Cd accumulation and elevated ALT, AST, and ALP, reduced TAC, and increased NO and MDA. Gul-BuOH significantly reduced hepatic Cd levels by 2.6- and 3.2-fold, restored TAC by 38.3% and 83.2%, and decreased NO (56.3% and 63.4%) and MDA (45.4% and 54.6%) at 100 and 200 mg/kg, respectively. Inflammatory markers NF-κB-p and TNF-α were markedly suppressed, while miRNA Let-7a was upregulated and lncRNA HOTAIR was downregulated. Histological and immunohistochemical analyses revealed near-complete restoration of hepatic architecture and normalization of HO-1 and Sirt-1 expression at the high dose. Serum metabolomics’ OPLS-DA model performance indicators demonstrated strong reliability, with an R2Y (explained variance) of 0.991 and a Q2 (predictive variance) of 0.988). The model identified 36 significantly altered metabolites that were largely normalized by Gul-BuOH, implicating linoleic acid metabolism, amino acid biosynthesis, and ascorbate-related pathways. Conclusion Gul-BuOH affords dose-dependent protection against Cd-induced liver injury by modulating oxidative stress, inflammation, metal detoxification, and metabolic pathways, supporting the traditional use of G. ulmifolia and its potential as a multi-target hepatoprotective agent.
O. A. Elsabagh, Abdelbaset M. Elgamal, Heba A. Hassan et al.· PLoS ONE· 0 citations
Cisplatin (Cis), a commonly used chemotherapy drug, is associated with liver toxicity, which restricts its broader clinical use. This study investigated the potential protective effects of linagliptin (Lina), a DPP‐4 inhibitor, in preventing liver damage induced by Cis in rats. There were four groups of male rats: a control group, a Cis group (8 mg/kg, IP), and cotreated groups given Lina (5 and 10 mg/kg, orally) with Cis. Lina was administered daily for 15 days, with Cis injected on Day 8. Liver function, oxidative stress markers, inflammatory mediators, energy metabolism indicators, and key signaling proteins were assessed. Cis administration resulted in significant hepatotoxicity, evidenced by elevated liver enzymes, increased oxidative stress, enhanced inflammatory response, and disrupted energy metabolism. Lina treatment, particularly at the 10‐mg/kg dose, demonstrated marked hepatoprotective effects. It significantly reduced liver enzyme levels, improved antioxidant status, attenuated inflammatory markers, and restored energy metabolism indicators. Moreover, Lina positively modulated essential signaling proteins involved in cellular stress response and metabolism, including signal transducer and activator of transcription 3 (STAT3), transforming growth factor beta 1 (TGF‐β), silent information regulator 1 (SIRT1), and peroxisome proliferator–activated receptor gamma coactivator 1‐alpha (PGC‐1α). The results indicate that Lina protects against Cis‐induced liver damage by leveraging its antioxidant, anti‐inflammatory, and metabolic regulation properties. This study offers new insights into potential strategies for mitigating Cis‐induced hepatotoxicity and enhancing its therapeutic index in cancer treatment.
M. A. Elbaset, Bassim M S A Mohamed, Passant E. Moustafa et al.· Advances in pharmacological...· 0 citations